“Hugel, a South Korean medical aesthetics leader, suffered temporary share price consolidation after slightly missing quarterly expectations. Despite this, the long-term investment thesis remains strong due to its cost-efficient production, attractive valuation, and impending U.S. regulatory approvals that will accelerate international expansion.”
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.